Category: Mergers & Acquisitions
The U.S. Federal Trade Commission has approved the pending $43 billion merger between Medtronic and Covidien, according to regulatory filings.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?: J&J demands $7.2 billion from Boston Scientific as trial begins; Will Orange County's medtech scene lose its juice without Allergan?; BD-CareFusion deal passes US anti-trust waiting period; Sources: Stryker weighs bid for Smith & Nephew
, Becton Dickinson & Co.
, Boston Scientific
, CareFusion Corp.
, Guidant Corp.
, Johnson & Johnson
, Smith & Nephew
, Stryker Corp.
, Valeant Pharmaceuticals
, Allergan Inc.
Abaxis says it bought QCR & Trio Diagnostics, the company's distribution partner for veterinary products in the U.K. and Ireland.
Abaxis said it bought QCR & Trio Diagnostics, its distribution partner for veterinary products in the U.K. and Ireland.
The deal closed on Nov. 17, Abaxis said. Financial terms were not disclosed.
Becton Dickinson plans to cut the debt load from its $12 billion acquisition of CareFusion by some $1.4 billion after realizing it has more cash available that it thought.
Bayer is reportedly exploring a sale of its diabetes device business, which could fetch as much as $2.5 billion from interested private equity buyers.
(Reuters) — Bayer (PINK:BAYRY) is considering the sale of its diabetes device business, Bloomberg reported, citing sources.
Anonymous sources confirm speculation that Stryker is weighing a bid for British orthopedics rival Smith & Nephew.
Speculation mounts again about a possible Stryker offer for Smith & Nephew now that a 6-month no-bid period has ended.
UPDATED Nov. 24 with analysis from Morgan Stanley.